Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase EARLY_PHASE1 2Phase 1 2Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Neoplasms 2Lung Neoplasms 2Gliosarcoma 2Glioblastoma 2Carcinoma, Renal Cell 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Tuberculosis, Pulmonary 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Salivary Gland Neoplasms 1Rhabdoid Tumor 1Rectal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Esthesioneuroblastoma, Olfactory 1Endometrial Neoplasms 1Colonic Neoplasms 1Chordoma 1Breast Neoplasms, Male 1

Interventions

Dexamethasone 133Lenalidomide 58Bortezomib 56Calcium Dobesilate 43Melphalan 41carfilzomib 38pomalidomide 36Cyclophosphamide 35daratumumab 23belantamab mafodotin 21Peripheral Blood Stem Cell Transplantation 17ixazomib 16dexamethasone acetate 13Filgrastim 13Bendamustine Hydrochloride 13fludarabine phosphate 12fludarabine 12dexamethasone 21-phosphate 12Tacrolimus 12auricularum 11Whole-Body Irradiation 11liposomal doxorubicin 10iberdomide 10Prednisone 10venetoclax 9selinexor 9Mycophenolic Acid 9pembrolizumab 8isatuximab 8Cyclosporine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Multiple Myeloma × Fluorodeoxyglucose F18 × Clear all
NCT07463807 2026-05-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

National Cancer Institute (NCI)

Phase 1/2 Not yet recruiting
162 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡